Modified gangliosides may be overexpressed in certain types of cancer, thus, they are considered a valuable target in cancer immunotherapy. Structural knowledge of their interaction with antibodies is currently limited, due to the large size and high flexibility of these ligands. In this study, we apply our previously developed site mapping technique to investigate the recognition of cancer-related gangliosides by anti-ganglioside antibodies. The results reveal a potential ganglioside-binding motif in the four antibodies studied, suggesting the possibility of structural convergence in the anti-ganglioside immune response. The structural basis of the recognition of ganglioside-mimetic peptides is also investigated using site mapping and compared to ganglioside recognition. The peptides are shown to act as structural mimics of gangliosides by interacting with many of the same binding site residues as the cognate carbohydrate epitopes. These studies provide important clues as to the structural basis of immunological mimicry of carbohydrates.
Citation: Agostino M, Yuriev E, Ramsland PA (2012) Antibody Recognition of Cancer-Related Gangliosides and Their Mimics Investigated Using in silico Site Mapping. PLoS ONE 7(4): e35457. https://doi.org/10.1371/journal.pone.0035457
Editor: Bostjan Kobe, University of Queensland, Australia
Received: February 6, 2012; Accepted: March 19, 2012; Published: April 20, 2012
Copyright: © 2012 Agostino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a small grant from the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, to EY. MA is a recipient of the Monash University Postgraduate Publication Award. PAR is the Sir Zelman Cowen Senior Research Fellow (Sir Zelman Cowen Fellowship Fund, Burnet Institute). The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Gangliosides are glycosphingolipids which feature one or more sialic acid residues. They are most often associated with nervous system function, where they play a crucial role in maintaining the stability of myelin and axons . Alterations in ganglioside expression levels have been associated with several neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease and HIV-associated dementia . The production of anti-ganglioside antibodies is one of the key biochemical features of Guillain-Barré syndrome, an autoimmune neuropathy . While the specific cause of the syndrome is unknown in the majority of cases, it is commonly preceded by infection with Campylobacter jejuni , .
Gangliosides have been identified as tumor-associated carbohydrate antigens (TACAs), a group which includes Lewis Y, Lewis X, Thomsen-Friedenreich and Thomsen-nouvelle . The gangliosides most often found in the nervous system are GM1, GD1a, GD1b and GT1b , however, the gangliosides considered for vaccine and antibody-based targeting are generally biosynthetic intermediates of these, such as GM2, GM3, GD2 and GD3 , , ,  (Figure 1). While found in low amounts in the nervous system, they often appear in high densities on a variety of tumor cell types , , ; thus, they are attractive targets for cancer immunotherapy. In addition to these, gangliosides terminating in N-glycolylneuraminic acid (Neu5Gc), such as N-glycolyl GM3 (Neu5Gc-GM3), are also useful targets for cancer treatment , . Unlike N-acetylneuraminic acid, Neu5Gc cannot be synthesized by humans, due to the lack of a functional sialic acid hydroxylase . The appearance of Neu5Gc on human cells is thought to come about through enzymatic incorporation from diet . Since Neu5Gc expression is largely restricted to cancer cells in humans, targeting Neu5Gc-terminating gangliosides is likely to achieve a highly selective therapeutic outcome.
CNS gangliosides: A. GT1b. B. GD1a. C. GD1b. D. GM1. Cancer-related gangliosides: E. GD2. F. GD3. G. GM3. H. Neu5Gc-GM3. Since each structure is differentiated by the removal of one or more residues from GT1b, the glycosidic linkages specified on GT1b apply to all of the structures, including Neu5Gc-GM3. Carbohydrate symbols follow the nomenclature of the Consortium for Functional Glycomics : N-acetylneuraminic acid – purple diamond; galactose – yellow circle; N-acetylgalactosamine – yellow square; glucose – blue circle; N-glycolylneuraminic acid – light blue diamond.
Carbohydrates are normally considered T cell-independent antigens, typically incapable of inducing a strong immune response , . One way to address this issue is through the development of carbohydrate mimetics, capable of inducing an anti-carbohydrate immune response. Peptides have been considered for this purpose against a wide range of targets . Peptide mimics of the GD2 , ,  and GD3 ,  gangliosides have been identified, typically by phage display against anti-ganglioside antibodies. Some of these have been found to induce anti-ganglioside immune responses , , . Peptide mimics of anti-Neu5Gc-GM3 antibodies are not currently known, however, anti-idiotypic antibodies against these antibodies have been identified , .
Although prior structural studies into the recognition of gangliosides and their mimics by antibodies have been performed , , , , these have generally utilized simple molecular docking methodologies. We have previously developed the site mapping technique, which we have demonstrated to be effective for studying carbohydrate-antibody ,  and carbohydrate-lectin recognition , as well as peptide-antibody recognition , , , . Here, we evaluate a range of molecular docking programs for their ability to predict the binding modes of acidic sugars to antibodies and apply our site mapping technique to study antibody recognition of acidic sugars (Table 1). The computational approach most suitable for the validation cases is then utilized to investigate recognition of carbohydrate epitopes of gangliosides by four anti-ganglioside antibodies: R24, ME36.1, chP3 and 14F7 (Table 2). While there are experimentally solved native structures of all of the antibodies of interest available, the structure of one of these antibodies, chP3, is missing a short segment of the key HCDR3 loop. We have thus extended the site mapping technique to consider multiple protein conformers, in a process termed “dynamic site mapping”. Finally, the site mapping technique is used to investigate antibody recognition of ganglioside-mimetic peptides, which is compared to recognition of the carbohydrate determinants of gangliosides.
Validation and test systems
For method validation, high resolution complexes (<2.5 Å) of the antichlamydial antibodies S25-2, S73-2 and S25-39 with poly-Kdo (ketodeoxyoctulosonic acid) antigens were obtained from the Protein Data Bank (PDB) (Table 1). The test systems examined (anti-ganglioside antibodies and their ligands) are summarized in Table 2. Antibodies were numbered and CDRs defined following the IMGT unique numbering scheme .
Glide 5.6 , , GOLD 4.1.1 , AutoDock 4.2  and DOCK 6.4  were evaluated for their ability to reproduce the crystallographic binding mode in each of the validation systems. The settings used for these programs are detailed elsewhere , . Briefly, the ligands were treated flexibly by each docking program, with the exception of the pyranose rings, which were kept in chair conformations. In the validation cases, all crystallographic waters and buffer molecules, as well as ions, were removed from the structures. The Protein Preparation Wizard in Maestro 9.2  was used to add hydrogens and determine the most likely protonation states of titratable protein residues in all cases.
The site mapping procedure was applied to the test systems as described previously . Briefly, the interactions taking place in the top 100 ranked poses obtained from molecular docking are tallied according to the protein residue with which they occurred and the type of interaction taking place (i.e., hydrogen bond or van der Waals interaction). The tallies are normalized by dividing the number of interactions observed with a particular residue by the total number of interactions observed. Normalization is performed separately for hydrogen bonding and van der Waals interactions. The normalized tallies are sorted from greatest to least contribution, and the cumulative sum is calculated. All residues which occur above a given cumulative sum cutoff are deemed important for recognition.
The metrics of reproduction and correctness were used in the assessment of site map quality. Reproduction is calculated as the number of crystallographic interactions identified by the site map divided by the number of crystallographic interactions observed. Correctness is calculated as the number of crystallographic interactions identified by the site map divided by the total number of mapped interactions. Reproduction and correctness values close to one indicate that the generated site maps accurately identify the crystallographic interactions, without the inclusion of erroneous contacts. The product of reproduction and correctness was used to assess the quality of mapping; larger values indicate optimal reproduction and correctness. The cumulative sum cutoff was optimized for the validation systems by assessing the average product of reproduction and correctness at 10% cutoff intervals from 0–100%. The cutoff which provided the greatest average product for the series of validation cases (Table 1) was applied to investigate the recognition of gangliosides and ganglioside-mimetic peptides by the selected anti-ganglioside antibodies (Table 2).
Dynamic site mapping
Three residues of the HCDR3 loop are missing from the structure of chP3 (PDB 3IU4) . The missing portion was manually built, and low energy conformers of this portion, as well as the residue adjacent to each side of the missing portion (making a total of five residues), were generated using the loop refinement tool in Prime . The site mapping procedure (see above) was performed on the ten lowest energy conformers. The most likely conformer from the set was selected on the basis of its similarity to the ensemble average of the hydrogen bonding and van der Waals site maps. The ensemble average maps were calculated by averaging the interaction contributions of each mapped residue across the set of ten conformers. The similarity of each conformer's site maps to the ensemble average was determined using the following expression:where a is the cutoff for selection of important hydrogen bonding contacts (as a fraction), b is the cutoff for selection of important van der Waals contacts (as a fraction), r2HB is the correlation coefficient calculated between a particular conformer and the ensemble average for hydrogen bonding contacts, and r2vdW is the correlation coefficient calculated between a particular conformer and the ensemble average for van der Waals contacts. The conformer exhibiting the highest similarity to the ensemble average maps was selected as the most likely conformer.
Peptide mimicry of gangliosides
Ganglioside-mimetic peptides were separated into overlapping hexapeptide fragments and docked to the antibody targets using GOLD. The site mapping technique (see above) was applied to the resulting ensembles of poses. The interaction data for the set of hexapeptides was pooled to give one set of site maps for the complete peptides, as described earlier .
Comparison of ganglioside and mimic recognition
To compare the recognition of gangliosides and their peptide-based mimics, scatter plots comparing the interaction contributions of antibody residues in ganglioside recognition and mimic recognition were generated. The distance between each point and the line representing equivalence of ganglioside and mimic recognition (d) was computed as described previously . Positive d values indicate a greater number of interactions by that residue with the mimic, while negative d values indicate more interactions with the ganglioside. Residues with d greater than an absolute value of 3.00 were considered to vary significantly from the equivalence line.
Molecular docking evaluation
Several molecular docking programs were evaluated for their ability to predict the crystallographic binding mode of a series of antichlamydial antibodies in complex with poly-Kdo antigens (Table 1). The results of molecular docking evaluation demonstrate that most programs are generally unsuccessful in accurately ranking the crystallographic binding mode (Table 3). However, all of the programs were able to identify the correct binding mode (i.e., less than 2.0 Å rmsd between pose and crystallographic binding mode) for at least one case, regardless of ranking. The exception to this is GOLD, which was able to both accurately identify and rank, as the top pose, the correct binding mode in four cases, these being all of the S73-2 complexes (PDB codes 3HZK, 3HZV and 3HZY), and the complex of S25-39 with Kdoα(2→4)Kdoα(2-OAll) (PDB 3OKK). Two of these successful cases are shown in Figure 2. In general, increasing the size and flexibility of the carbohydrate determinant being examined led to reduced quality predictions. Furthermore, the binding site topography may also impact on the quality of predictions, as observed previously , however, too few appropriate model complexes are available to confirm this.
A. Comparison of top ranked pose obtained from molecular docking (yellow) with the crystallographic binding mode (blue) of the Kdoα(2→4)Kdoα(2-OAll):S25-39 complex (PDB 3OKK). B. Comparison of top ranked pose (yellow) obtained from molecular docking with the crystallographic binding mode (blue) of the Kdoα(2→8)Kdoα(2→4)Kdoα(2-OAll):S73-2 complex (PDB 3HZV). C. Schematic representation of interactions in the Kdoα(2→4)Kdoα(2-OAll):S25-39 predicted by molecular docking. D. Schematic representation of interactions in the Kdoα(2→8)Kdoα(2→4)Kdoα(2-OAll):S73-2 complex. Molecular docking carried out using GOLD 4.1.1. Figures 2A and 2B prepared using PyMOL . Figures 2C and 2D prepared using LIGPLOT . Legend to Figures 2C and 2D: hydrogen bonds – green dashes; hydrophobic interactions – red arcs; carbon – black; oxygen – red; nitrogen – blue; ligand bonds – purple; protein bonds – orange.
Optimization of site mapping for antibody recognition of acidic sugars
Since GOLD produced the most accurate poses, irrespective of the ability to rank those poses, it was used to provide the pose ensemble input for site mapping. A cumulative sum cutoff of 80% for both hydrogen bonding and van der Waals interactions has been shown to be optimal when site mapping anti-carbohydrate antibodies, where shorter, less flexible and less functionally diverse carbohydrates were considered . This cutoff has also been successfully applied to peptide-recognizing antibodies and carbohydrate-lectin interactions , . In order to determine whether this cutoff was appropriate for studying antibody recognition of acidic sugars with highly flexible linkages (i.e., (1→6) or (2→8) linkages), a range of cutoff values was investigated (Table S1). The 90% cutoff was found to be most consistent, affording a lower standard deviation in the product data (i.e., reproduction×correctness) obtained for the set of cases (S.D. = 0.05). The 80% cutoff afforded an identical mean to the 90% cutoff across the set of studied cases, but was slightly less consistent than the 90% cutoff (S.D. = 0.08). However, the use of the 90% cutoff resulted in relatively poor map correctness (∼0.5–0.6) compared to previous cases , , . This low level of map correctness can be attributed to the inclusion of many erroneous van der Waals contacts.
In order to optimize the selection of interacting residues, hydrogen bonds and van der Waals contacts were considered with separate cutoffs, instead of the same cutoff for each interaction type as previously used , , . When hydrogen bonding was considered alone, the 90% cutoff was found to be optimal for the range of test systems (Table S2) and gave superior results to considering both hydrogen bonding and van der Waals with the same cutoff. Consideration of some van der Waals contacts is needed to identify interactions with non-polar sidechains. It was found that a 40% cutoff for van der Waals contacts, in combination with a 90% cutoff for hydrogen bonding interactions, provided the optimal prediction of crystallographic contacts (Table S3).
Using this optimized cutoff, it was demonstrated that site mapping and the top pose obtained from molecular docking performed comparably at the prediction of interacting residues (Figure 3, Table 4). Furthermore, this optimized cutoff affords site map quality comparable in reproduction and correctness to previously studied antibody- and lectin-carbohydrate systems , .
Kdoα(2→4)Kdoα(2→4)Kdoα(2-OAll) binding to S73-2 (PDB 3HZY) described by hydrogen bonding map (A) and van der Waals interaction map (B). Kdoα(2→8)Kdoα(2→4)Kdoα(2-OAll) binding to S25-39 (PDB 3OKO) described by hydrogen bonding map (C) and van der Waals interaction map (D). The color depth indicates the level of involvement of a particular residue in ligand recognition; more strongly illuminated residues are more involved in ligand recognition than weakly illuminated residues. The crystal structure binding mode is shown in each structure in sticks colored by atom type (C, yellow; O, red). Images rendered using PyMOL .
Dynamic site mapping of chP3
The structure of chP3 (PDB 31U4) is missing three residues from the HCDR3 loop . It is known that residues from this loop are important for antigen recognition by chP3. In order to identify the most appropriate conformation of this loop, “dynamic” site mapping of chP3, whereby site mapping of multiple chP3 conformers – varying only in the conformation of the missing portion of the HCDR3 loop – was carried out. Since less than ten poses were obtained when docking Neu5Gc-GM3 to the fourth-lowest energy conformer of the chP3 HCDR3, site mapping could not be carried out on this structure. The eleventh-lowest energy conformer was used instead, to make a set of ten structures.
From site-directed mutagenesis studies, it is known that Arg111.2H (Arg100AH in Kabat numbering) is critical for ganglioside recognition . It would therefore be expected that this residue is heavily involved in antigen interactions. When the site mapping procedure was carried out on the lowest energy chP3 HCDR3 conformer, Arg111.2H accounted for only 5.31% of all observed hydrogen bonds, while other residues accounted for a significantly greater number of hydrogen bonds (Table S4). Thus, the top scoring conformer is potentially not the most representative of the biologically relevant state. Similar site maps to this were observed for the fifth- and ninth-lowest energy chP3 structures. The second-lowest energy chP3 HCDR3 conformer featured almost no interactions with Arg111.2H (0.90% of hydrogen bonds and 1.34% of van der Waals interactions), suggesting that the loop is also likely to be in a biologically irrelevant conformation. Upon inspection of this structure, the side-chain of Arg111.2H stacks with the side-chain of Trp57H, and thus cannot easily interact with the ligand (Figure 4). In the third-lowest energy structure, the most hydrogen bonds were observed with Arg111.2H – just over 20% of all hydrogen bonds. Therefore, this structure is likely to be representative of the biologically relevant state. Other key contacts in this structure included Ala112.1H, His107L and Tyr108L. The sixth-lowest energy structure featured Arg111.2H and Ala112.1H as key contacts, but does not prominently feature the two residues from the light chain, identified as important for interactions in the third-lowest energy structure. Instead, Ser38H was identified as a key contact. The eighth-lowest energy structure was similar to this, with slightly greater emphasis on interactions with His107L and Tyr108L. In the seventh-lowest energy structure, Arg111.2H dominated the hydrogen bonding interactions, accounting for almost one third of all hydrogen bonds observed with that structure. However, Ala112.1H, Gln112H, His107L and Tyr108L each accounted for ∼10% of all hydrogen bonds. The tenth- and eleventh-lowest energy structures afforded similar site maps to one another, with hydrogen bonds fairly evenly distributed between Arg112.2H, Ala112.1H, Gln112H, Ala113H, His107L and Tyr108L.
A. The second-lowest energy conformer, highlighting the stacking between the side-chains of Arg111.2H and Trp57H. B. The tenth-lowest energy conformer, predicted to be most likely to be involved in ligand binding. C. Hydrogen bonding site map for tenth-lowest energy conformer. D. The van der Waals map for tenth-lowest energy conformer. Residues contributing to the proposed ganglioside-binding motif are highlighted on the hydrogen bonding site maps.
In all cases, van der Waals contacts were dominated by Trp57H and Trp116L (Table S5). The HCDR3 residues – Arg111.2H, Ala112.1H and Gln112H – were also important for van der Waals contacts. Their importance is usually in line with their importance for hydrogen bonding (i.e., residues that are strongly important for hydrogen bonding are typically strongly important for van der Waals contacts).
In analyzing the generated site maps, it was determined that the chP3 conformer most representative of the average state was the tenth-ranked conformer (Figure 4, Table 5). This conformer features significant hydrogen bonding with Arg111.2H, known to be important for recognition from site-directed mutagenesis studies, but also suggests the importance of nearby HCDR3 residues (Ala112.1H, Gln112H, Ala113H) and the LCDR3 residues His107L and Tyr108L. The van der Waals interactions largely occur with tryptophan residues at positions 57H and 116L. This residue utilization is similar to other anti-carbohydrate antibodies .
Determination of the likely ganglioside-recognizing motif
We had investigated ganglioside recognition by the four anti-ganglioside antibodies (Table 2) using identical hydrogen bonding and van der Waals cutoffs, as per our previous work , , , and this identified some of the residues likely to be involved in ganglioside recognition . To confirm the results of this preliminary study, these cases have now been re-examined using the optimized cutoff values. The corresponding carbohydrate epitopes of the gangliosides were docked to R24, ME36.1 and 14F7, and the optimized cutoffs were applied to identify likely antibody residues involved in ganglioside recognition. The generated site maps, as well as that generated by the dynamic mapping procedure applied to chP3, were used to identify the presence of a potential ganglioside-binding motif in the anti-ganglioside antibodies. The key residues involved in ganglioside recognition are summarized in Table 6.
Ganglioside recognition by the antibodies was generally dominated by interactions with the heavy chain (Figures 4 and 5). In the cases of mAbs R24 and 14F7, recognition was entirely dependent on heavy chain residues, while for mAbs ME36.1 and chP3, approximately one third of all interactions occurred with light chain residues. These differences in CDR utilization can be explained in terms of the binding site topographies of each of the antibodies; the binding cavities of R24 and 14F7 are both comprised entirely of heavy chain residues, with access to the LCDRs blocked by HCDR2.
Hydrogen bonding and van der Waals site maps of R24 (A and B), ME36.1 (C and D) and 14F7 (E and F). Residues contributing to the likely ganglioside-binding motif are labeled on the hydrogen bonding site maps.
Despite the differences in binding site topographies, there are key similarities between the antibodies which become apparent upon structural examination of the site maps. Four residues, arranged in a relatively similar “spiral” around each antibody binding site, are largely responsible for hydrogen bonding interactions with the gangliosides. Proceeding clockwise, the likely ganglioside-binding motif of the antiganglioside antibodies comprises two polar residues (typically Ser, followed by Tyr, Thr or Asp), an aromatic residue (typically Tyr) and a basic residue (Arg). Not all of the antibodies strictly conform to this motif; for example, R24 features a threonine residue where an arginine would be expected, and chP3 features an alanine residue where a serine would be expected.
Peptide mimicry of gangliosides
The peptide mimic of GD3 – RHAYRSMAEWGFLYS – could replicate almost all of the van der Waals interactions made by the ganglioside with R24, but some marked differences in the hydrogen bonding profile occurred (Table S6). The maps revealed that the peptide failed to replicate the number of hydrogen bonds made between the GD3 trisaccharide and the antibody residues Gly38H and Ser58H. However, a significant increase in hydrogen bonds with the HCDR3 residues, Tyr113H and Tyr114H, was observed. The reduced potential of the peptide to deeply and consistently penetrate the binding site across the pose ensemble may explain why fewer interactions were observed with Gly38H and Ser58H. Tyr113H and Tyr114H may afford more interactions with the peptide, since they are more easily accessible. From comparison of the ganglioside- and peptide-derived site maps (Figure 6), the peptide appears to be a partial structural mimic of GD3 . This partial structural mimicry could account for the observed immunological mimicry of GD3 by this peptide .
A. Hydrogen bonding site map describing peptide (RHAYRSMAEWGFLYS) recognition by R24. B. van der Waals interaction site map describing peptide recognition by R24. Site maps generated and rendered using PyMOL . C. Comparison of hydrogen bonding site maps describing GD3 and peptide recognition. D. Comparison of van der Waals site maps describing GD3 and peptide recognition. In Figures 6C and 6D, open points indicate residues which deviate significantly from the line representing equivalence of carbohydrate and peptide interactions (i.e., |d|>3.00). The open point not labeled on Figure 6C corresponds with Tyr114H.
The peptide mimic of GD2 could more closely mimic carbohydrate binding to ME36.1 compared to the peptide mimic of GD3 binding to R24 (Table S7). Similar to carbohydrate and peptide binding to R24, the van der Waals interactions of the carbohydrate were very well replicated by the peptide, while some minor differences in the hydrogen bonding profile were observed. A significant increase in hydrogen bonds with Asp55H and Ser108H was observed, accompanied by a slight drop in hydrogen bonds with Tyr55L and Ser56L. Despite these differences, the ganglioside- and peptide-derived site maps for ME36.1 are overall very similar to one another. Since the peptide is known to be an immunogenic mimic of GD2 , this represents a case of structural mimicry translating into immunological mimicry (Figure 7) .
A. Hydrogen bonding site map describing peptide (LDVVLAWRDGLSGAS) recognition by ME36.1. B. van der Waals interaction site map describing peptide recognition by ME36.1. C. Comparison of hydrogen bonding site maps describing GD2 and peptide recognition. D. Comparison of van der Waals site maps describing GD2 and peptide recognition.
Carbohydrate-protein recognition is particularly challenging for molecular docking to predict accurately, due to the multitude of chemically equivalent hydroxyl groups in carbohydrates and their potential to form many specific interactions, including CH-π interactions , . Evaluation of a variety of molecular docking approaches against suitable test cases is desirable to ensure the development of an optimal modeling protocol. We have previously demonstrated that molecular docking can be an effective tool for studying antibody recognition of structurally simpler carbohydrates . However, gangliosides feature diverse chemical functionality, including carboxylate groups and flexible hydroxylated chains. Furthermore, GD2 and GD3 contain α(2→8) linkages, which feature an additional degree of conformational freedom compared to, for example, (1→3) and (1→4) linkages, which we have previously investigated . To our knowledge, such systems have not been appropriately evaluated with molecular docking. While high resolution ganglioside-antibody complexes are not available for use in method evaluation, a series of high resolution structures of antichlamydial antibodies in complex with Kdo-containing carbohydrates are available , ,  (Table 1); these represent the most suitable model systems for evaluating the likelihood of success in predicting ganglioside-antibody recognition. Another issue with molecular docking is the need to consider the potential of multiple ligand binding modes. Their effect on recognition by proteins may be important for highly flexible ligands, such as carbohydrates and peptides . In order to consider the effect of multiple ligand binding modes on recognition by proteins , we developed the site mapping technique, which we have demonstrated to be effective for studying carbohydrate-antibody  and carbohydrate-lectin recognition , as well as carbohydrate-peptide mimicry .
In this study, the site mapping methodology is extended to study the recognition of acidic sugars, particularly gangliosides, by antibodies. Furthermore, to study ganglioside recognition by chP3, a “dynamic” version of the site mapping technique was developed, whereby multiple antibody conformers are considered to select one with the most likely ligand-binding conformation. Ganglioside mimicry is investigated by comparing the site maps describing the recognition of gangliosides and their peptide-based mimics.
All of the antibodies examined in the validation set (Table 1) prominently feature arginine residues in their binding sites, which pair with the carboxylate groups of the complexed carbohydrate. Since these charge-assisted hydrogen bonds are likely to be highly energetically favorable, it was anticipated that the pairing effect would lead to good quality predictions of antibody recognition of acidic sugars. The pairing effect gives rise to good quality predictions in GOLD for four of the validation cases. However, increasing both the number of residues as well as the flexibility of the carbohydrate (i.e., including one or more α(2→8) linkages) generally results in reduced accuracy. This result is not surprising, as these factors are known to affect the accuracy of molecular docking . Furthermore, the carbohydrates in the validation cases contain multiple carboxylate groups, therefore, it is possible that the incorrect carboxylate group could be paired against a specific arginine residue, particularly if the rest of molecule can be accommodated in the binding site and favorably scored. This is not an issue for the majority of the test cases (Table 2), which feature only one carboxylate group. Since only a limited number of antibodies are available for use as validation cases, the effect of binding site topography on docking accuracy could not be effectively studied, as it had been previously , . However, the case of 3HZV, which contains a large, highly flexible carbohydrate, suggests that subtle changes in binding site topography have a dramatic impact on docking accuracy.
In our previous site mapping studies, identical cutoffs of hydrogen bonding and van der Waals interactions were used to select residues involved in ligand recognition , , . However, the use of identical cutoffs for both of these interaction types does not result in an optimal model for gangliosides. A significant bias towards hydrogen bonding interactions is needed to accurately represent antibody recognition of acidic sugars. Furthermore, consideration of van der Waals interactions resulted in only a slight improvement in the overall accuracy of the site mapping procedure. This suggests that hydrogen bonding interactions are significantly more important for antibody recognition of acidic sugars than van der Waals interactions. Systems previously studied via site mapping , ,  may benefit from this “mixed” treatment of hydrogen bonding and van der Waals interactions.
The dynamic mapping study of chP3 demonstrates that the site mapping technique has applications not just in identifying antibody residues important for ligand interactions, but also in identifying the likely bioactive conformation of CDR loops, particularly HCDR3, which is often crucial for antigen recognition and for which no canonical structures exist , . Importantly, the selected protein conformer did not correspond with the lowest energy state identified, suggesting that, at least in the case of chP3, conformational change upon antigen binding may be important in recognition. The role of conformational change and induced-fit mechanisms in antigen binding has been explored earlier by a number of groups , , , , . The dynamic mapping study highlights the potential usefulness of the site mapping technique in the homology modeling of antibodies and in the structural elucidation of conformational change upon antigen binding.
Although the four anti-ganglioside antibodies studied have quite distinct binding site topographies and varying specificities (Table 2), enough similarities in residue utilization across the set could be identified to propose a potential ganglioside-binding motif. This suggests the possibility of structural convergence in the immune response towards a given antigen class. Structural convergence has been reported earlier for anti-Lewis Y antibodies . It is likely that anti-ganglioside antibodies specifically recognize terminal sialic acid residues, since these are the most accessible, and thus, antibodies may consistently contain a particular sialic acid-binding motif. Structural analysis of additional anti-ganglioside antibodies is required in order to evaluate this hypothesis. The currently identified motif provides a potential framework for optimizing existing anti-ganglioside antibodies.
In comparing ganglioside and peptide recognition, we were able to determine that peptides known to act as immunological mimics of gangliosides could also act at least as partial structural mimics of the gangliosides. Therefore, it may be possible to design peptides which are capable of inducing an anti-ganglioside immune response using the antibody site maps generated in this study. Such a “design by mapping” procedure was proposed in our earlier work in investigating peptide mimicry of αGal-terminating carbohydrates . Our results for docking anti-idiotypic antibodies to anti-Neu5Gc-GM3 antibodies indicate that anti-idiotypic antibodies do not act as structural mimics of gangliosides. This is most likely due to protein-protein recognition involving a more extensive interaction network compared with protein-carbohydrate association.
While the site mapping technique solely evaluates ligand recognition from the protein's “point-of-view”, it can be combined with ligand-based mapping techniques to provide the complete picture of ligand-protein recognition . Thus, this study not only suggested how gangliosides and their mimics are recognized by antibodies, but also raised several important new lines of inquiry relevant to future development of our mapping techniques. Studies are currently underway to answer these new questions, which will contribute to the robustness of the mapping techniques in probing carbohydrate-antibody recognition and to better understanding such recognition.
To summarize our findings, the anti-ganglioside antibodies studied here largely utilize a motif of four residues to recognize gangliosides (Ser, polar, aromatic, Arg). These residues are arranged within the binding site of each antibody studied here in a relatively similar fashion. Peptides which bind to anti-ganglioside antibodies and elicit anti-ganglioside immune responses were found to act as structural mimics of the gangliosides, providing a case where structural mimicry translates into immunological mimicry. Our findings provide structural details invaluable for the future development of ganglioside-targeting cancer vaccines or optimizing therapeutic antibodies, as well as demonstrating the potential role of the site mapping technique in structure-based vaccine design.
Initial optimization of site mapping cutoff using validation systems.
Optimization of site mapping cutoff for hydrogen bonding using validation systems.
Optimization of site mapping cutoff for van der Waals interactions using validation systems.
Hydrogen bonding interactions in top ranked HCDR3 conformers of chP3.
van der Waals interactions in top ranked HCDR3 conformers of chP3.
Comparison of carbohydrate and peptide recognition by R24.
Conceived and designed the experiments: MA EY PAR. Performed the experiments: MA. Analyzed the data: MA. Wrote the paper: MA EY PAR.
- 1. Schnaar RL (2010) Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Letters 584: 1741–1747.RL Schnaar2010Brain gangliosides in axon-myelin stability and axon regeneration.FEBS Letters58417411747
- 2. Posse de Chaves E, Sipione S (2010) Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Letters 584: 1748–1759.E. Posse de ChavesS. Sipione2010Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction.FEBS Letters58417481759
- 3. Kusunoki S, Kaida K-i (2011) Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders. J Neurochem 116: 828–832.S. KusunokiK-i Kaida2011Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders.J Neurochem116828832
- 4. Koga M, Yuki N, Hirata K (1999) Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Neuroimmunol 96: 245–250.M. KogaN. YukiK. Hirata1999Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barre syndrome after Campylobacter jejuni enteritis.J Neuroimmunol96245250
- 5. Neisser A, Schwerer B, Bernheimer H, Moran AP (2000) Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barre syndrome. J Neuroimmunol 102: 85–88.A. NeisserB. SchwererH. BernheimerAP Moran2000Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barre syndrome.J Neuroimmunol1028588
- 6. Hakomori S-I (2001) Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491: 369–402.S-I Hakomori2001Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.Adv Exp Med Biol491369402
- 7. Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9: 308–324.RD AstronomoDR Burton2010Carbohydrate vaccines: developing sweet solutions to sticky situations?Nat Rev Drug Discov9308324
- 8. Navid F, Santana VM, Barfield RC (2010) Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10: 200–209.F. NavidVM SantanaRC Barfield2010Anti-GD2 antibody therapy for GD2-expressing tumors.Curr Cancer Drug Targets10200209
- 9. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM (2003) Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Exp Rev Vaccines 2: 817–823.LE FernandezDF AlonsoDE GomezAM Vazquez2003Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.Exp Rev Vaccines2817823
- 10. Fredman P, Hedberg K, Brezicka T (2003) Gangliosides as therapeutic targets for cancer. Biodrugs 17: 155–167.P. FredmanK. HedbergT. Brezicka2003Gangliosides as therapeutic targets for cancer.Biodrugs17155167
- 11. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, et al. (2009) Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58: 1117–1128.Y. DiazA. GonzalezA. LopezR. PerezAM Vazquez2009Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma.Cancer Immunol Immunother5811171128
- 12. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P (2010) Tumor-associated carbohydrate antigens in breast cancer. Breast Cancer Res 12: 204.A. CazetS. JulienM. BobowskiJ. BurchellP. Delannoy2010Tumor-associated carbohydrate antigens in breast cancer.Breast Cancer Res12204
- 13. Wolchok JD, Livingston PO (2001) Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2: 205–211.JD WolchokPO Livingston2001Vaccines for melanoma: translating basic immunology into new therapies.Lancet Oncol2205211
- 14. Inoue S, Sato C, Kitajima K (2010) Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology 20: 752–762.S. InoueC. SatoK. Kitajima2010Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells.Glycobiology20752762
- 15. Fernández LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, et al. (2010) NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010: 814397.LE FernándezMR GabriMD GuthmannRE GomezS. Gold2010NGcGM3 ganglioside: a privileged target for cancer vaccines.Clin Dev Immunol2010814397
- 16. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, et al. (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95: 11751–11756.HH ChouH. TakematsuS. DiazJ. IberE. Nickerson1998A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence.Proc Natl Acad Sci USA951175111756
- 17. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, et al. (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100: 12045–12050.P. TangvoranuntakulP. GagneuxS. DiazM. BardorN. Varki2003Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid.Proc Natl Acad Sci USA1001204512050
- 18. Mond JJ, Lees A, Snapper CM (1995) T cell-independent antigens type 2. Annu Rev Immunol 13: 655–692.JJ MondA. LeesCM Snapper1995T cell-independent antigens type 2.Annu Rev Immunol13655692
- 19. Snapper CM, Mond JJ (1996) A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 157: 2229–2233.CM SnapperJJ Mond1996A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens.J Immunol15722292233
- 20. Agostino M, Sandrin MS, Thompson PE, Farrugia W, Ramsland PA, et al. (2011) Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications. Expert Opin Biol Ther 11: 211–224.M. AgostinoMS SandrinPE ThompsonW. FarrugiaPA Ramsland2011Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications.Expert Opin Biol Ther11211224
- 21. Forster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, et al. (2005) Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol 42: 319–325.E. Forster-WaldlAB RiemerAK DehofD. NeumannK. Bramswig2005Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.Mol Immunol42319325
- 22. Horwacik I, Czaplicki D, Talarek K, Kowalczyk A, Bolesta E, et al. (2007) Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library. Int J Mol Med 19: 829–839.I. HorwacikD. CzaplickiK. TalarekA. KowalczykE. Bolesta2007Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.Int J Mol Med19829839
- 23. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, et al. (2008) Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 57: 1079–1089.A. WondimuT. ZhangT. Kieber-EmmonsP. GimottyK. Sproesser2008Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.Cancer Immunol Immunother5710791089
- 24. Willers J, Lucchese A, Kanduc D, Ferrone S (1999) Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 20: 1021–1026.J. WillersA. LuccheseD. KanducS. Ferrone1999Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside.Peptides2010211026
- 25. Popa I, Ishikawa D, Tanaka M, Ogino K, Portoukalian J, et al. (2006) GD3-replica peptides selected from a phage peptide library induce a GD3 ganglioside antibody response. FEBS Letters 580: 1398–1404.I. PopaD. IshikawaM. TanakaK. OginoJ. Portoukalian2006GD3-replica peptides selected from a phage peptide library induce a GD3 ganglioside antibody response.FEBS Letters58013981404
- 26. Horwacik I, Kurcinski M, Bzowska M, Kowalczyk AK, Czaplicki D, et al. (2011) Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a. Int J Mol Med 28: 47–57.I. HorwacikM. KurcinskiM. BzowskaAK KowalczykD. Czaplicki2011Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.Int J Mol Med284757
- 27. Vázquez AM, Pérez A, Hernández AM, Macías A, Alfonso M, et al. (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17: 527–534.AM VázquezA. PérezAM HernándezA. MacíasM. Alfonso1998Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.Hybridoma17527534
- 28. Rodriguez M, Llanes L, Perez A, Perez R, Vazquez AM (2003) Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. Hybridoma Hybridomics 22: 307–314.M. RodriguezL. LlanesA. PerezR. PerezAM Vazquez2003Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside.Hybridoma Hybridomics22307314
- 29. Krengel U, Olsson L-L, Talavera A, Rojas G, Mier E, et al. (2004) Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 279: 5597–5603.U. KrengelL-L OlssonA. TalaveraG. RojasE. Mier2004Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3.J Biol Chem27955975603
- 30. Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, et al. (2009) Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 46: 3466–3475.A. TalaveraA. ErikssonM. OkvistA. Lopez-RequenaY. Fernandez-Marrero2009Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody.Mol Immunol4634663475
- 31. Usuki S, Taguchi K, Gu Y-H, Thompson SA, Yu RK (2010) Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: use of peptide glycomimics. J Neurochem 113: 351–362.S. UsukiK. TaguchiY-H GuSA ThompsonRK Yu2010Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: use of peptide glycomimics.J Neurochem113351362
- 32. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA (2009) In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. Mol Immunol 47: 233–246.M. AgostinoMS SandrinPE ThompsonE. YurievPA Ramsland2009In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies.Mol Immunol47233246
- 33. Milland J, Yuriev E, Xing P.-X., McKenzie I.F.C., Ramsland PA, Sandrin MS (2007) Carbohydrate residues downstream of the terminal Galα(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Immunol Cell Biol 85: 623–632.J. MillandE. YurievP.-X. XingI.F.C. McKenziePA RamslandMS Sandrin2007Carbohydrate residues downstream of the terminal Galα(1,3)Gal epitope modulate the specificity of xenoreactive antibodies.Immunol Cell Biol85623632
- 34. Agostino M, Yuriev E, Ramsland PA (2011) A computational approach for exploring carbohydrate recognition by lectins in innate immunity. Front Immunol 2: 23.M. AgostinoE. YurievPA Ramsland2011A computational approach for exploring carbohydrate recognition by lectins in innate immunity.Front Immunol223
- 35. Yuriev E, Ramsland PA, Edmunson AB (2001) Docking of combinatorial peptide libraries into a broadly cross-reactive human IgM. J Mol Recognit 14: 172–184.E. YurievPA RamslandAB Edmunson2001Docking of combinatorial peptide libraries into a broadly cross-reactive human IgM.J Mol Recognit14172184
- 36. Agostino M, Sandrin MS, Thompson PE, Ramsland PA, Yuriev E (2011) Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. Biopolymers 96: 193–206.M. AgostinoMS SandrinPE ThompsonPA RamslandE. Yuriev2011Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens.Biopolymers96193206
- 37. Yuriev E, Ramsland PA, Edmundson AB (2002) Recognition of IgG-derived peptides by a human IgM with an unusual combining site. Scand J Immunol 55: 242–255.E. YurievPA RamslandAB Edmundson2002Recognition of IgG-derived peptides by a human IgM with an unusual combining site.Scand J Immunol55242255
- 38. Yuriev E, Sandrin MS, Ramsland PA (2008) Antibody-ligand docking: insights into peptide-carbohydrate mimicry. Mol Simul 34: 461–468.E. YurievMS SandrinPA Ramsland2008Antibody-ligand docking: insights into peptide-carbohydrate mimicry.Mol Simul34461468
- 39. Lefranc M-P, Pommié C, Manuel R, Giudicelli V, Foulquier E, et al. (2003) IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27: 55–77.M-P LefrancC. PommiéR. ManuelV. GiudicelliE. Foulquier2003IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains.Dev Comp Immunol275577
- 40. Schrödinger, LLC (2010) Glide, version 5.6. Schrödinger, LLC2010Glide, version 5.6.New York, NY. New York, NY.
- 41. Friesner RA, Banks JL, Murphy RB, Halgren TA, Kilcic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004: 1739–1749.RA FriesnerJL BanksRB MurphyTA HalgrenJJ Kilcic2004Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.J Med Chem 200417391749
- 42. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609–623.ML VerdonkJC ColeMJ HartshornCW MurrayRD Taylor2003Improved protein-ligand docking using GOLD.Proteins52609623
- 43. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639–1662.GM MorrisDS GoodsellRS HallidayR. HueyWE Hart1998Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.J Comput Chem1916391662
- 44. Lang PT, Brozell SR, Mukherjee S, Pettersen EF, Meng EC, et al. (2009) DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 15: 1219–1230.PT LangSR BrozellS. MukherjeeEF PettersenEC Meng2009DOCK 6: combining techniques to model RNA-small molecule complexes.RNA1512191230
- 45. Agostino M, Jene C, Boyle T, Ramsland PA, Yuriev E (2009) Molecular docking of carbohydrate ligands to antibodies: structural validation against crystal structures. J Chem Inf Model 49: 2749–2760.M. AgostinoC. JeneT. BoylePA RamslandE. Yuriev2009Molecular docking of carbohydrate ligands to antibodies: structural validation against crystal structures.J Chem Inf Model4927492760
- 46. Schrödinger, LLC (2010) Maestro, version 9.2. Schrödinger, LLC2010Maestro, version 9.2.New York, NY. New York, NY.
- 47. Schrödinger, LLC (2010) Prime, version 2.2. Schrödinger, LLC2010Prime, version 2.2.New York, NY. New York, NY.
- 48. Agostino M, Farrugia W, Sandrin MS, Scott AM, Yuriev E, et al. (2012) Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy. In: Kosma P, Müller-Loennies S, editors. Anticarbohydrate antibodies - from molecular basis to clinical application. New York: Springer. pp. 203–228.M. AgostinoW. FarrugiaMS SandrinAM ScottE. Yuriev2012Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy.P. KosmaS. Müller-LoenniesAnticarbohydrate antibodies - from molecular basis to clinical applicationNew YorkSpringer203228
- 49. Yuriev E, Agostino M, Ramsland PA (2011) Challenges and advances in computational docking: 2009 in review. J Mol Recognit 24: 149–164.E. YurievM. AgostinoPA Ramsland2011Challenges and advances in computational docking: 2009 in review.J Mol Recognit24149164
- 50. Nguyen HP, Seto NOL, MacKenzie CR, Brade L, Kosma P, et al. (2003) Germline antibody recognition of distinct carbohydrate epitopes. Nat Struct Biol 10: 1019–1025.HP NguyenNOL SetoCR MacKenzieL. BradeP. Kosma2003Germline antibody recognition of distinct carbohydrate epitopes.Nat Struct Biol1010191025
- 51. Brooks CL, Müller-Loennies S, Borisova SN, Brade L, Kosma P, et al. (2010) Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition. Biochemistry 49: 570–581.CL BrooksS. Müller-LoenniesSN BorisovaL. BradeP. Kosma2010Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition.Biochemistry49570581
- 52. Blackler RJ, Müller-Loennies S, Brooks CL, Evans DW, Brade L, et al. (2011) A common NH53K single point mutation in the combining site of antibodies raised against chlamydial LPS glycoconjugates significantly increases avidity. Biochemistry 50: 3357–3368.RJ BlacklerS. Müller-LoenniesCL BrooksDW EvansL. Brade2011A common NH53K single point mutation in the combining site of antibodies raised against chlamydial LPS glycoconjugates significantly increases avidity.Biochemistry5033573368
- 53. Gorelik B, Goldblum A (2008) High quality binding modes in docking ligands to proteins. Proteins 71: 1373–1386.B. GorelikA. Goldblum2008High quality binding modes in docking ligands to proteins.Proteins7113731386
- 54. Al-Lazikani B, Lesk AM, Chothia C (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273: 927–948.B. Al-LazikaniAM LeskC. Chothia1997Standard conformations for the canonical structures of immunoglobulins.J Mol Biol273927948
- 55. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196: 901–917.C. ChothiaAM Lesk1987Canonical structures for the hypervariable regions of immunoglobulins.J Mol Biol196901917
- 56. James LC, Roversia P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299: 1362–1367.LC JamesP. RoversiaDS Tawfik2003Antibody multispecificity mediated by conformational diversity.Science29913621367
- 57. Herron JN, He XM, Ballard DW, Blier PR, Pace PE, et al. (1991) An autoantibody to single-stranded DNA: comparison of the three-dimensional structures of the unliganded Fab and a deoxynucleotide-Fab complex. Proteins 11: 159–175.JN HerronXM HeDW BallardPR BlierPE Pace1991An autoantibody to single-stranded DNA: comparison of the three-dimensional structures of the unliganded Fab and a deoxynucleotide-Fab complex.Proteins11159175
- 58. Krishnan L, Sahni G, Kaur KJ, Salunke DM (2008) Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry. Biophys J 94: 1367–1376.L. KrishnanG. SahniKJ KaurDM Salunke2008Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry.Biophys J9413671376
- 59. Thielges MC, Zimmermann J, Yu W, Oda M, Romesberg FE (2008) Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition. Biochemistry 47: 7237–7247.MC ThielgesJ. ZimmermannW. YuM. OdaFE Romesberg2008Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition.Biochemistry4772377247
- 60. Wilson IA, Stanfield RL (1994) Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 4: 857–867.IA WilsonRL Stanfield1994Antibody-antigen interactions: new structures and new conformational changes.Curr Opin Struct Biol4857867
- 61. Ramsland PA, Farrugia W, Bradford TM, Hogarth PM, Scott AM (2004) Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol 340: 809–818.PA RamslandW. FarrugiaTM BradfordPM HogarthAM Scott2004Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.J Mol Biol340809818
- 62. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA (2010) Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. Glycobiology 20: 724–735.M. AgostinoMS SandrinPE ThompsonE. YurievPA Ramsland2010Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps.Glycobiology20724735
- 63. Nomenclature Committee, Consortium for Functional Glycomics. Nomenclature Committee, Consortium for Functional Glycomics.Symbol and text nomenclature for representation of glycan structure. Available from: http://glycomics.scripps.edu/CFGnomenclature.pdf. Accessed 2011 Dec 1. Symbol and text nomenclature for representation of glycan structure. Available from: http://glycomics.scripps.edu/CFGnomenclature.pdf. Accessed 2011 Dec 1.
- 64. Schrödinger, LLC (2010) Schrödinger, LLC2010The PyMOL Molecular Graphics System, Version 1.4. The PyMOL Molecular Graphics System, Version 1.4.
- 65. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Prot Eng 8: 127–134.AC WallaceRA LaskowskiJM Thornton1995LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions.Prot Eng8127134
- 66. Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, et al. (1999) The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular β-sheet between interaction between VH domains. J Biol Chem 274: 5597–5604.MJ KaminskiCR MacKenzieMJ MooibroekTE DahmsT. Hirama1999The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular β-sheet between interaction between VH domains.J Biol Chem27455975604
- 67. Pichla SL, Murali R, Burnett RM (1997) The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol 119: 6–16.SL PichlaR. MuraliRM Burnett1997The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside.J Struct Biol119616